P-BCMACD19-ALLO1

N/A

Report date: 2023/08/17 16:40:38

Base Information

Drug NameP-BCMACD19-ALLO1
Drug Alias NameP-BCMACD19-ALLO1BCMA/CD19 dual-target CAR-T cell immunotherapy(Poseida Therapeutics Inc)BCMA/CD19 dual-targeting CAR-T therapy(Poseida Therapeutics Inc)Dual CAR-BCMA-19(Poseida Therapeutics Inc)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-BCMAAnti-CD19
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPoseida Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPoseida Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A